NASDAQ$INDV
Indivior Pharmaceuticals Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Indivior reported Q2 2025 revenue of $302.0M, net income of $18.0M, diluted EPS of $0.14.
For Q2 2025, Indivior reported Revenue was $302.0M, net income was $18.0M, diluted EPS was $0.14. Management discusses segment trends, liquidity, and outlook in the quarterly filing.
- Revenue $302.0M for Q2 2025.
- Net income $18.0M.
- Diluted EPS $0.14.
Headline financials
Revenue & EPS history
Indivior · Revenue · Quarterly
$302M
Forward guidance
Healthcare outlook emphasizes utilization, reimbursement, and capital allocation.
Tailwinds
- Scale in pharmacy, insurance, or therapeutics franchises.
- Pipeline and partnership milestones where relevant.
Headwinds
- Medical cost trends and regulatory change.
- Patent cliffs and pricing pressure.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 10 quarterly earnings reports · overlaid with Q2 2025
+7.2%
Avg return
Earnings day
+12.4%
Avg return
5 days after
+871.4%
Avg return
30 days after
73%
8 / 11 earnings
Positive
+24.4%
Q4 2023
Best reaction
-16.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.7% | +15.9% | — | |
| Q4 2025 | +0.2% | -8.2% | -13.9% | |
| Q3 2025 | +15.4% | +26.8% | +33.1% | |
| Q2 2025 | +16.1% | +25.3% | +39.5% | |
| Q1 2025 | +17.3% | +24.3% | +8632.9% | |
| Q3 2024 | +7.0% | +7.0% | +27.1% | |
| Q2 2024 | +19.2% | +8.3% | -5.4% | |
| Q1 2024 | -7.0% | +25.5% | +13.1% | |
| Q4 2023 | +24.4% | +27.1% | +19.3% | |
| Q3 2023 | -16.0% | -9.4% | -21.5% | |
| Q2 2023 | -5.4% | -6.8% | -10.1% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro